Research Spotlight: Nate Lavoy

Our scientists bring a wealth of immunology research expertise from diverse backgrounds. With extensive experience in a variety of biologics disciplines, our team is an ideal resource for a wide range of outsource research services. From multiplex assays to flow cytometric analyses, we help you get on with discovery. In this Researcher Spotlight, we introduce…

Read more

Now Available: MAGE-A10 Antigen-Specific T Cells

MAGE-A10 is highly expressed in triple-negative breast cancers (Estrogen Receptor / Progesterone Receptor / HER-2-negative), an important focus for many cancer researchers. We have developed a new T cell line specific for the MAGE-A10254-263 peptide (GLYDGMEHL) and restricted by HLA-A*0201. These MAGE-A10 T cells could be the perfect complement to your cancer immunotherapy research. View…

Read more

New: Anti-HER2/neu T Cells for Early Stage Research

What is the HER2 Antigen? HER2 is a tumor-related antigen also known as ERBB2 or NEU. The HER2 gene encodes a human epidermal growth factor receptor (EGFR) that is overexpressed by several tumor types, most notably in breast and ovarian cancers.  Many women (and men) are interested to know their HER2 status. HER2 gene amplification…

Read more

Meet Us at the CAR-TCR Summit in London

  The CAR-TCR Summit is heading to London! We will be represented at the show by our partners from Key Biologics, who will be ready to meet you at booth A10. If you’re working to engineer a cancer-free world, come talk to us about how we can help with cell sourcing in the UK and…

Read more

Phacilitate 2020: A Focus on Patient Voices

Phacilitate 2020 was jam-packed with inspiration, motivation, and confirmation that what we are doing is making an impact on patient lives now and into the future. We attended several educational sessions, met with many scientists, and had countless conversations about the future of immunotherapy. Here are some of our top Phacilitate 2020 highlights.   2020…

Read more